Effects of the selective kainate receptor antagonist ACET on altered sensorimotor gating in a genetic model of reduced NMDA receptor function by Duncan, Gary E. et al.
Effects of the selective kainate receptor antagonist ACET on
altered sensorimotor gating in a genetic model of reduced
NMDA receptor function
Gary E. Duncan1,2, Beverly H. Koller3, and Sheryl S. Moy1,2
1Department of Psychiatry University of North Carolina at Chapel Hill
2Carolina Institute for Developmental Disabilities University of North Carolina at Chapel Hill
3Department of Genetics University of North Carolina at Chapel Hill
Abstract
The pathophysiology of schizophrenia may involve reduced NMDA receptor function.
Accordingly, experimental models of NMDA receptor hypofunction may be useful for testing
potential new antipsychotic agents and for characterizing neurobiological abnormalities relevant to
schizophrenia. We demonstrated previously that mice under-expressing the NR1 subunit of the
NMDA receptor show supersensitive behavioral responses to kainic acid and that a kainate
receptor antagonist normalized altered behaviors in the mutant mice (NR1neo/neo). The present
work examined effects of another selective kainate receptor antagonist, (S)-1-(2-Amino-2-
carboxyethyl)-3-(2-carboxy-5-phenylthiophene-3-yl-methylpyrimidine-2,4-dione (ACET), on
altered behavioral phenotypes in the genetic model of NMDA receptor hypofunction. ACET, at a
dose of 15 mg/kg, partially reversed the deficits in prepulse inhibition produced by the mutation.
The 15 mg/kg dose of ACET was also effective in reversing behavioral effects of the selective
kainate agonist ATPA. However, ACET did not significantly reduce the increased locomotor
activity and rearing behavior observed in the NR1neo/neo mice. These findings show that a highly
selective kainate receptor antagonist can affect the deficits in sensorimotor gating in the
NR1neo/neo mice. The results also provide further support for the idea that selective kainate
receptor antagonists could be novel therapeutic candidates for schizophrenia.
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Altered glutamate mediated neurotransmission has been suggested to play a role in the
pathophysiology of schizophrenia. The most compelling evidence in this regard is the well-
documented effects of NMDA receptor antagonists to induce a spectrum of behavioral
alterations in healthy humans that mimic positive, cognitive and affective symptoms of
schizophrenia (Javitt and Zukin, 1991; Krystal et al., 1994). In addition, NMDA antagonists
precipitate symptoms in stabilized schizophrenia patients (Lahti et al., 1995).
Based on the NMDA hypofunction hypothesis of schizophrenia, Mohn et al. (1999)
developed a novel mutant mouse model characterized by markedly reduced expression of
the NR1 subunit of the NMDA receptor. The partial disruption of NR1 subunit expression
was produced by insertion of a neomycin resistance cassette into intron 20 of the NR1
(Grin1) locus. This insertion mutation results in a marked under-expression of the NR1
subunit to approximately 10% of wild type values in all regions examined (Mohn et al.,
1999; Ramsey et al., 2008). The homozygous NR1neo/neo mutant animals are sometimes
referred to as NR1 hypomorphic or NR1 knock-down, since expression of the gene is
reduced, but not eliminated.
The NR1neo/neo mice exhibit a number of behavioral phenotypes that support their utility to
model certain behavioral characteristics of schizophrenia. These phenotypes include reduced
locomotor habituation in a novel environment (Duncan et al., 2002; Mohn et al., 1999) and
deficits in prepulse inhibition of acoustic startle (PPI) (Duncan et al., 2004; Duncan et al.,
2006a; Duncan et al., 2006b; Fradley et al., 2005). In addition, the mutant mice show
enhanced sensitivity to amphetamine-induced disruption of PPI (Moy et al., 2006). The
NR1neo/neo mice also show marked deficits in tests of social affiliation and social aggression
(Duncan et al., 2004; Halene et al., 2009; Mohn et al., 1999). Behavioral alterations in the
NR1neo/neo mice are reduced by administration of typical and atypical antipsychotic drugs,
although the atypical drugs exhibit a distinct behavioral profile compared the typical drugs
in the model (Duncan et al., 2006a; Duncan et al., 2006b; Mohn et al., 1999).
We recently discovered that the NR1neo/neo mice exhibit an increase in sensitivity to seizure
producing effects of systemically administered kainic acid, an agonist of a kainate subtype
of glutamate receptors (Duncan et al., 2010). To test the hypothesis that increased kainate
receptor sensitivity to endogenous glutamate could contribute to the abnormal behavioral
phenotypes of the NR1neo/neo mice, a highly selective kainate receptor antagonist,
LY382884, was given to the mice before assessment of prepulse inhibition of acoustic
startle and activity in an open field (Duncan et al., 2010). The drug completely normalized
the exaggerated baseline startle response of the mutant mice but had no effect on startle
amplitude in the controls. LY382884 increased PPI in both wild type and control mice. The
drug also reduced the hyperactivity in horizontal locomotion and rearing behavior in the
NR1neo/neo mice, without affecting activity in the wild type mice. It is of interest that the
behavioral profile of LY382884 in the mutant mice is similar to that of several atypical
antipsychotic drugs tested in the model (Duncan et al., 2006a; Duncan et al., 2006b).
LY382884 has relatively low potency as a kainate antagonist and penetrates the brain
poorly. However, these initial studies open an interesting door of possibilities: that kainate
antagonists could have efficacy in the treatment of schizophrenia. In order to further pursue
this exciting prospect, the present work tested another highly selective and more potent
kainate antagonist in the NR1 hypomorphic model, (S)-1-(2-Amino-2-carboxyethyl)-3-(2-
carboxy-5-phenylthiophene-3-yl-methylpyrimidine-2,4-dione, abbreviated ACET (Dargan et
al., 2009; Jane et al., 2009).
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2.1 ACET blockade of ATPA-induced immobility
Optimal doses for ACET efficacy in behavioral assays were determined by an initial screen,
using only wild type mice, against the characteristic immobility following i.p. administration
of ATPA, the tert-butyl analogue of AMPA. In previous studies, ATPA was identified as an
AMPA agonist (Ornstein et al., 1996), but was later discovered to be a selective agonist of
the GluK1 (formerly GluR5) kainate receptor (Hoo et al., 1999; Jane et al., 2009). In the
present study, ATPA (30 mg/kg, i.p.) consistently induced a state of complete immobility
and flat body posture in all mice tested. However, if the mice were picked up they would
exhibit typical activation and when returned to the cage would move briefly, but then
become immobile with the flat body posture. Pretreatment with a low dose of ACET (7.5
mg/kg, s.c.), given one hour before ATPA, failed to attenuate immobility. However, a higher
dose of ACET (15 mg/kg) antagonized ATPA-induced behavioral suppression and all 5
mice tested at this dose demonstrated normal ambulatory activity. Therefore, we utilized 7.5
mg/kg and 15 mg/kg as low and moderate doses of ACET for the acoustic startle and
activity tests (described below).
2.2 Receptor binding profile of ACET at non-glutamate receptors
Although the specificity of ACET for the kainate subtype of glutamate receptors is well
documented, there is no information available for potential off-target non-glutamatergic
receptor selectivity. The ability of ACET to bind to a wide range of receptors was examined
and results reported in the supplementary data. The receptors examined included subtypes of
serotonin, norepinephrine, dopamine, histamine, acetylcholine, and monoamine transporters.
Results of this screening process showed no appreciable binding affinity of ACET for any
receptor tested, with Ki values ranging from 3,000 nM to >10,000 nM (Table 1,
supplemental).
2.3 Effects of ACET on acoustic startle and PPI in wild type and NR1neo/neo mice
The NR1 hypomorphic mice showed the expected increased startle responses and reduced
PPI, in comparison to the wild type subjects. Overall repeated measures analyses revealed
significant interactions between genotype, treatment, and decibel level for amplitude
[F(5,345)=3.9, p=0.0019] and ppi [F(4,276)=3.21, p=0.0135]. The analyses also revealed
significant effects of ACET dose for each measure [amplitude, interaction between
genotype, dose, and decibel level, F(5,345)=3.72, p=0.0027; ppi, treatment × dose
interaction, F(1,69)=9.81, p=0.0025]. Separate analyses were then conducted to determine
treatment effects at each ACET dose (7.5 or 15 mg/kg).
In the cohort of mice tested with the lower dose of ACET (7.5 mg/kg), repeated measures
ANOVAs indicated highly significant main effects of genotype on startle amplitude
[F(1,31)=11.69, p=0.0018] and PPI [F(1,31)=20.74, p<0.0001], but no significant main
effects or interactions for ACET treatment (Figures 1 and 2). In contrast, the higher dose of
ACET (15 mg/kg) had significant effects on startle amplitude (Figure 3) and on PPI (Figure
4), dependent upon genotype. Similar to the cohort of mice used to assess the 7.5 mg/kg
dose of ACET, in the cohort used to test the15 mg/kg dose the overall repeated measures
ANOVAs revealed significant main effects of genotype for startle amplitudes
[F(1,38)=26.93, p<0.0001] and PPI [F(1,38)=29.33, p<0.0001]. However, the analyses also
indicated an ACET treatment × genotype interaction for amplitude [F(1,38)=5.66,
p=0.0224], and a highly significant main effect of ACET treatment for PPI [F(1,38)=7.93,
p=0.0077].
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Separate repeated measures ANOVAs conducted for the wild type and mutant mice revealed
that ACET (15 mg/kg) had significant effects in the NR1neo/neo, but not the wild type mice.
In the mutant mice, ACET produced significant decreases in startle responses [main effect
of treatment, F(1,15)=5.65, p=0.0311] and significant enhancement of prepulse inhibition
[main effect of treatment, F(1,15)=4.55, p=0.0499]. However, the effect of ACET on startle
response for the pulse-alone trial did not reach statistical significance for the wild type or
mutant mice. The lack of significant effect of ACET on startle response for the pulse-alone
trial suggests that the overall treatment effect on startle indicated by the ANOVA was due to
the drug's effect on PPI.
2.4 Effects of ACET on locomotion and rearing in wild type and NR1neo/neo mice
To examine potential effects of ACET (15 mg/kg) on locomotor activity, a separate cohort
of mice was tested in the activity chambers without prior acoustic startle testing. Wild type
and mutant mice were injected s.c. with vehicle or ACET (8–10 mice/group) 1 hr before
being placed in the activity chambers and data collected for 1 hr in the chambers (Figure 5).
Within-genotype analyses indicated that the significant ACET effect on locomotion was
present in the NR1neo/neo group [treatment × time interaction, F(11,154)=2.18, p=0.0179].
However, post-hoc analysis indicated no significant effect of ACET for any time point for
either genotype. Similar analyses on the rearing measure revealed significant interactions
between treatment and time were observed in both the wild type [F(11,176)=1.9, p=0.0424]
and mutant [F(11,154)=2.33, p=0.0113] groups but post-hoc analysis found no significant
effect of ACET for either genotype at any time point.
3. Discussion
There is compelling need to develop better pharmacologic therapies for schizophrenia.
Currently available drugs are associated with severe adverse side effects and limited efficacy
for cognitive and affective dimensions of the illness. Traditional animal models have played
a critical role in development of new antipsychotic drugs. However, standard models based
on blocking effects of dopamine agonists have not resulted in discovery of drugs with
therapeutic efficacy that is substantially better than first generation antipsychotic drugs
(Lieberman et al., 2005; Swartz et al., 2007).
The present work demonstrated that the highly selective kainate receptor antagonist ACET
diminished the deficits in PPI in NR1 hypomorphic mice. These mutant mice represent a
unique animal model of schizophrenia based on the NMDA hypofunction hypothesis of the
illness. The previously demonstrated ability of therapeutically effective antipsychotic drugs
to normalize behavioral abnormalities in the NR1neo/neo mice supports the predictive validity
of the model (Duncan et al., 2006a; Duncan et al., 2006b). Accordingly, our previous work
with LY382884 (Duncan et al. 2010) and the present findings with ACET suggest that
selective kainate receptor antagonists could be a novel class of antipsychotic drugs.
Kainate receptors in the brain are composed of various combinations of 5 distinct subunits
(designated GluK1–5 in the current IUPHAR nomenclature). Both LY382884 and ACET
are selective for the GluK1 (formerly GluR5) subtype of the kainate receptor, and both drugs
had similar effects to reduce startle reactivity and increase PPI in the NR1neo/neo mice.
LY382884 also normalized the locomotor hyperactivity and increased rearing behavior
observed in the mutant mice. The magnitude of response to the kainate antagonists in the
with regard to reduction in startle and increased PPI in the NR1neo/neo is similar to that
observed for other antipsychotic drugs tested in the model, including risperidone, clozapine,
quetiapine, olanzapine (Duncan et al., 2006a; Duncan et al., 2006b). However, ACET had
no clear effect on the increased horizontal locomotor activity or rearing associated with the
mutation. Further work will be required to determine the reasons for the apparently different
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behavioral pharmacological profiles of ACET and LY382884 in the NR1 hypomorphic
mice.
Preclinical studies predict low behavioral toxicity for kainate antagonists selective for the
GluK1 subtype. In the present study, no reduction in locomotor activity was found in the
wild type or mutant mice for ACET at a dose that was effective in normalizing the
exaggerated startle and PPI deficits in the NR1neo/neo mice. In studies of protection from
electrically induced seizures by a range of glutamate antagonists, LY382884 was the only
drug in a series of glutamatergic agents that did not produce rotarod deficits at any dose
tested (Barton et al., 2003).
Genetic studies in human populations have shown polymorphisms of GRIK3, which encodes
the kainate 3 receptor subtype, are associated with schizophrenia. In subjects from northern
Italy (Begni et al., 2002), Scandinavia (Djurovic et al., 2009), and India (Ahmad et al.,
2009), a polymorphism of the GRIK3 gene was found to be associated with schizophrenia.
However, genetic analyses conducted in Japanese (Shibata et al., 2006) and Chinese (Li et
al., 2008) populations did not find an association with the GRIK3 polymorphism and
schizophrenia.
Altered binding of 3H-kainic acid and expression of mRNAs for specific subunits of the
kainate receptor have been reported in schizophrenia patients (Beneyto et al., 2007; Deakin
et al., 1989; Kerwin et al., 1990; Meador-Woodruff and Healy, 2000; Scarr et al., 2005;
Watis et al., 2008). Most studies found reduced 3H-kainic acid binding and reduced
expression of select mRNAs encoding subunits of the kainate receptor in specific cortical
and hippocampal regions. However, it is difficult to predict changes in function from static
measures of receptor binding or mRNA expression. For example, in a previous study with
the NR1 hypomorphic mice, we found no change in 3H-kainic acid binding in any brain
region in comparison to the wild type mice (Duncan et al., 2002). By contrast, the mutant
mice exhibited markedly increased behavioral sensitivity to challenge with kainic acid
(Duncan et al., 2010). Thus, the functional consequences of reduced expression of kainate
receptors reported in postmortem studies of schizophrenia are unknown.
Reduced kainate receptor binding and expression of kainate receptor subunit mRNAs in
people with schizophrenia could result from a loss of neurons expressing kainate receptors.
In a postmortem study of schizophrenia patients, the number of GABAergic neurons
specifically expressing the GluK1 subunit of the kainate receptor was reduced by 40% in the
anterior cingulate cortex (Woo et al., 2007). In another postmortem study, the numerical
density of neurons exhibiting immunoreactivity for kainic acid receptors was reduced in the
orbital frontal cortex (Garey et al., 2006). Excessive activation of kainate receptors is known
to produce neurotoxic effects. It is therefore possible that supersensitivity of kainate
receptors in select populations of neurons of schizophrenia patients could be involved in the
reported reduced number of neurons expressing kainate receptors in cortical regions.
Establishing a role for altered kainate receptor function in the pathophysiology of
schizophrenia will require further investigation. However, available postmortem and genetic
studies provide hints for alterations in kainate receptors in schizophrenia patients. The
activity of selective kainate receptor antagonists to partially normalize behavioral
abnormalities in the NR1 hypomorphic mouse model provides further incentive to explore
the potential of kainate receptor antagonists as novel antipsychotic agents.
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Littermate wild type and mutant NR1neo/neo mice were generated by breeding heterozygotic
mice, as previously described (Duncan et al., 2004). Animals from “stock” colonies of
129S6/SvEvTac NR1+/neo and C57BL/6J NR1+/neo mice (identified by PCR) were used to
set up matings to generate experimental animals, i.e., F1 hybrid NR1neo/neo and NR1+/+
littermates. In all cases, a 129S6/SvEvTac+/neo female was bred to a C57BL/6J+/neo male.
Experimental and control animals were considered genetically identical, with the caveat that
the F1 hybrid NR1neo/neo mice are homozygous for genes very tightly linked to the NR1
gene. However, the C57BL/6J heterozygous mice used to generate the F1 hybrids are at
N20, and therefore this linked region is predicted to be very small. Both male and female
mice were used in the studies, with group counter-balanced for gender as much as possible.
Mice were 3–7 months of age at the time of testing.
4.2 Drugs
(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxy-5-phenylthiophene-3-
ylmethylpyrimidine-2,4-dione) (ACET), and (RS)-2-Amino-3(hydroxy-5-tert-
butylisoxazol-4-yl)propionic acid (ATPA) were obtained from Tocris Bioscience, Ellisville,
MI. Both drugs were dissolved in 20% Captisol (Cydex Pharmaceuticals). ACET was
injected s.c. and ATPA was injected i.p.
4.3 Characterization of ACET by the Psychoactive Drug Screening Program
Although published data indicate that ACET is potent and selective kainate receptor
antagonist that has minimal affinity for other glutamate receptor subtypes, limited
information has been published about potential non-glutamate receptor off-target sites of
action of the drug. To better understand the pharmacology of ACET with respect to kainate
receptor specificity, receptor-binding profiles of the drug were assessed across a wide range
of receptors. This work was generously provided by the National Institute of Mental Health's
Psychoactive Drug Screening Program, contract # HHSN-271-2008-00025-C (NIMH
PDSP). The NIMH PDSP is directed by Bryan L. Roth MD, PhD at the University of North
Carolina at Chapel Hill and by Project Officer Jamie Driscol at NIMH, Bethesda MD, USA.
4.4 Behavioral observations and dose finding after ATPA and ACET administration
Wild type F1 hybrid mice were treated with ATPA (30 mg/kg, i.p.), a selective agonist of
the GluK1 subtype of the kainate receptor, placed into individual mouse cages, and
monitored for one hour for rigidity and immobility. At this dose, ATPA consistently induced
a state of complete immobility and flat body posture, beginning 5–10 min after injection,
and lasting approximately 30 min. Pretreatment with ACET (7.5 or 15 mg/kg) or vehicle,
given s.c., occurred one hour before the administration of ATPA, with 5 mice per treatment
group.
4.5 Effects of ACET on acoustic startle and prepulse inhibition
The acoustic startle measure was based on the reflexive whole-body flinch, or startle
response, following exposure to a sudden noise. Animals were tested with a San Diego
Instruments SR-Lab system using the procedure described by Paylor and Crawley (1997).
Briefly, mice were placed in a small Plexiglas cylinder within a larger, sound-attenuating
chamber (San Diego Instruments). The cylinder was seated upon a piezoelectric transducer,
which allowed vibrations to be quantified and displayed on a computer. The chamber
included a house light, fan, and a loudspeaker for the acoustic stimuli (bursts of white
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noise). Background sound levels (70 dB) and calibration of the acoustic stimuli were
confirmed with a digital sound level meter (San Diego Instruments).
The selective kainate receptor antagonist ACET was injected s.c. at doses of 7.5 or 15 mg/
kg, 60 min before placing mice in the startle chambers. Separate cohorts of mice were used
for each dose (N = 18 wild type and 17 mutant mice for the low dose group, and N = 25 wild
type and 17 mutant mice for the higher dose group). Each test session consisted of 42 trials,
presented following a five-minute habituation period. Seven different types of trials were
presented: no-stimulus (NoS) trials, trials with the acoustic startle stimulus (40 ms; 120 dB)
alone, and trials in which a prepulse stimulus (20 ms; either 74, 78, 82, 86, or 90 dB) had
onset 100 ms before the onset of the startle stimulus. The different trial types were presented
in blocks of 7, in randomized order within each block, with an average intertrial interval of
15 seconds (range: 10 to 20 seconds). Measures were taken of the startle amplitude for each
trial, defined as the peak response during a 65-msec sampling window that began with the
onset of the startle stimulus. An overall analysis was performed for each subject's data for
levels of prepulse inhibition at each prepulse sound level (calculated as 100 - [(response
amplitude for prepulse stimulus and startle stimulus together / response amplitude for startle
stimulus alone) × 100]).
4.6 Open field test
Locomotor activity was after injection with 15 mg/kg ACET, for 1-hr period in a photocell-
equipped automated open field (40 cm × 40 cm × 30 cm; Versamax system, Accuscan
Instruments). Activity chambers were contained inside sound-attenuating boxes, equipped
with houselights and fans. Measures were taken of horizontal activity and number of rearing
movements at 5-min intervals during the test.
4.7 Statistics
Behavioral data were first analyzed using an overall repeated measures ANOVA, with the
factors genotype (+/+ or neo/neo), treatment (vehicle or ACET), dose (7.5 or 15 mg/kg), and
either decibel level (the repeated measure for the acoustic startle test) or time (the repeated
measure for the open field test). The two measures from the startle test were amplitude and
prepulse inhibition, each analyzed separately. Because of significant dose effects in the
overall analysis, repeated measures ANOVAs with the factors genotype and treatment were
conducted for each dose of ACET. Significant effects of ACET were further explored by
separate repeated measures ANOVAs for each genotype, with the factor treatment. Fishers
Protected Least Significant Difference (PLSD) tests were conducted between group means
only when a significant F value was found in the repeated measures ANOVA. For all
comparisons, significance was set at p<0.05.
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> The effects of a highly selective kainate antagonist, ACET, was examined on
altered behavioral responses associated with reduced expression of the NR1
subunit of the NMDA receptors.
> ACET reduced the enhanced acoustic startle response and deficits in
sensorimotor gating in NR1 hypomorphic mice.
> The results also provide further support for the idea that selective kainate
receptor antagonists could be novel therapeutic candidates for schizophrenia.
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Acoustic startle response after ACET (7.5 mg/kg) in wild type and NR1 hypomorphic mice.
Data are means + SEMs. The number of female and male mice in the different groups are as
follows: Veh NR1+/+, female n=5, male n=4; ACET NR1+/+, female n=5, male n=4; Veh
NR1neo/neo, female n=4, male n=4, ACET NR1neo/neo, female n=5, male n=4. There was no
significant effect of ACET on startle response.
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Prepulse inhibition of acoustic startle after ACET (15 mg/kg) in wild type and NR1
hypomorphic mice. Data shown are means (+ SEM) for each group. There was no
significant effect of ACET for any prepulse level for wild type or mutant mice.
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Acoustic startle response after ACET (15 mg/kg) in wild type and NR1 hypomorphic mice.
Data are means + SEMs. The number of female and male mice in the different groups are as
follows: Veh NR1+/+, female n=7, male n=6; ACET NR1+/+, female n=6, male n=6; Veh
NR1neo/neo, female n=5, male n=3, ACET NR1neo/neo, female n=5, male n=4. * p<.05
compared to NR1neo/neo-Vehicle.
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Prepulse inhibition of acoustic startle after ACET (15 mg/kg) in wild type and NR1
hypomorphic mice. Data shown are means (+ SEM) for each group. * p<.05 compared to
NR1neo/neo-Vehicle.
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Horizontal activity (A) and rearing activity (B) in wild type and NR1 hypomorphic mice
after ACET (15 mg/kg). Data shown are means (± SEM) for each group. There was no
significant effect of ACET on horizontal distance traveled or rearing at any time point.
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